Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
about
Radioimmunoconjugates for treating cancer: recent advances and current opportunities.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Targeting HER2 in Nuclear Medicine for Imaging and Therapy.ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
P2860
Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Development and preclinical studies of 64Cu-NOTA-pertuzumab F
@nl
Development and preclinical st ...... onse to trastuzumab by PET/CT.
@en
type
label
Development and preclinical studies of 64Cu-NOTA-pertuzumab F
@nl
Development and preclinical st ...... onse to trastuzumab by PET/CT.
@en
prefLabel
Development and preclinical studies of 64Cu-NOTA-pertuzumab F
@nl
Development and preclinical st ...... onse to trastuzumab by PET/CT.
@en
P2093
P2860
P1476
Development and preclinical st ...... onse to trastuzumab by PET/CT.
@en
P2093
Conrad Chan
Raymond M Reilly
P2860
P304
P356
10.1080/19420862.2016.1255389
P577
2016-11-04T00:00:00Z